30.06.2010 • NewsLawsuitNigeriaPfizer

U.S. Top Court Rejects Pfizer Nigeria Lawsuit Appeal

The Supreme Court said on Tuesday that it rejected an appeal by Pfizer on a ruling that reinstated U.S. lawsuits by Nigerian families, who say the drugmaker tested an experimental antibiotic on their children without getting adequate consent. The justices declined to review a ruling by a U.S. appeals court in New York that allowed the lawsuits involving alleged harm caused by the drug Trovan to go forward.

Pfizer conducted clinical trials of the drug in Nigeria during a 1996 meningitis epidemic. Families of some of the children who participated said the tests caused deaths and various injuries. According to the lawsuits, Pfizer violated international law by failing to obtain adequate consent from the patients. The lawsuits sought unspecified damages on behalf of the children who were part of the study.

The drugmaker said the clinical study was conducted with the approval of the Nigerian government and it had the consent of participants' parents or guardians. Pfizer said the trial violated no international or Nigerian laws. Pfizer said the appellate ruling expanded the jurisdiction of the Alien Tort Statute, a more than 200-year-old law, to American corporations doing business abroad, raising issues of "national and international importance."

A federal judge initially dismissed the lawsuits, ruling the cases should be heard in Nigeria, not the U.S. In 1998, the U.S. Food and Drug Administration approved Trovan for use by adults only. After reports of liver failure, its use was restricted in this country to adult emergency care. The EU banned its use in 1999. The Obama administration urged the justices to reject Pfizer's appeal, saying the questions presented did not warrant Supreme Court review.

The court agreed and rejected the pharmaceutical company's appeal without any comment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
06.03.2025 • News

CordenPharma Expands Peptide Manufacturing Platform in Switzerland

Contract development and manufacturing organization (CDMO) CordenPharma has finalized plans to establish a new peptide manufacturing facility in Switzerland located at Getec Park in Muttenz near Basel. This investment is part of the company’s growth initiatives with a more than €1 billion strategic investment in peptide development and manufacturing.